Pacific Biomarkers Q2 Revenues Drop 35 Percent

Despite the results, CEO Ron Helm said that the company has "identified the biomarker services area as the long-term growth driver in a market segment where demand is strong and there are presently no dominant players."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories